Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937313 | 0.84 | MCHR1 (0.45) | MCHR1CYP19A1 | |
| SCHEMBL25937327 | 0.81 | MCHR1 (0.43) | MCHR1CYP19A1 | |
| SCHEMBL25937293 | 0.81 | S1PR4 (0.37) | MCHR1S1PR4CYP19A1GRIN1GRIN2B | |
| SCHEMBL25937318 | 0.81 | MCHR1 (0.43) | MCHR1CYP19A1 | |
| SCHEMBL25937297 | 0.80 | MCHR1 (0.42) | MCHR1 | |
| SCHEMBL25937329 | 0.80 | MCHR1 (0.42) | MCHR1CYP19A1 | |
| SCHEMBL25937320 | 0.80 | MCHR1 (0.42) | MCHR1CYP19A1 | |
| SCHEMBL25937316 | 0.79 | MCHR1 (0.41) | MCHR1CYP19A1 | |
| SCHEMBL25937311 | 0.79 | MCHR1 (0.41) | MCHR1CYP19A1 | |
| SCHEMBL25937312 | 0.79 | MCHR1 (0.44) | MCHR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MCHR1 4279/4885S1PR4 2246/4885CYP19A1 4459/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | MCHR1 4279/4885S1PR4 2246/4885CYP19A1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.